COMP <GO>
URGN vs PAHC // OPTIONS IMPLIED MOVE & PUT/CALL SKEW
UroGen Pharma Ltd. (NASDAQ) VS. Phibro Animal Health Corporation (Class A) (NASDAQ) • 15-METRIC TALLY: URGN 2
— PAHC 9
■ METRIC PARITY
LAST: $34.36 (+5.01%) • MKT CAP: $1.60B
options-implied-move
—
LAST: $38.74 (-0.36%) • MKT CAP: $1.58B
options-implied-move
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (URGN VS. PAHC)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | URGN | PAHC | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 88.70% | 30.90% | +57.80 | URGN | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | 9.90% | -44.90 | PAHC | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 19.2x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -9.94% | 5.08% | -15.02 | PAHC | /fcf-yield <GO> |
| Operating Margin | -60.00% | 8.50% | -68.50 | PAHC | /operating-margins <GO> |
| Net Profit Margin | -60.00% | 3.70% | -63.70 | PAHC | /net-margins <GO> |
| Revenue Growth (YoY) | 21.40% | 27.40% | -6.00 | PAHC | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 1.23% | -1.23 | PAHC | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 0.20 | 2.87 | -2.67 | PAHC | /balance-sheet <GO> |
| Piotroski F-Score Quality | 3/9 | 8/9 | -5.00 | PAHC | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew ACTIVE | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 29.7 | 56.9 | -27.20 | PAHC | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 27.5x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $1.60B | $1.58B | $20.8M | URGN | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | URGN REV | PAHC REV | URGN GROSS % | PAHC GROSS % | URGN FCF | PAHC FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $109.8M | $1.30B | 88.7% | 30.9% | -$162.7M | $80.1M |
| FY 2024 | $90.4M | $1.02B | 90.2% | 30.8% | -$97.1M | $87.6M |
| FY 2023 | $82.7M | $977.9M | — | — | -$76.4M | $13.3M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
URGN // BETA —
PAHC // BETA —